SciELO - Scientific Electronic Library Online

 
vol.82 número5Evaluación del perfil metabólico y prevalencia de enfermedad cardiovascular en los ex combatientes de la guerra de MalvinasLa ley de salud mental en Argentina índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

  • Não possue artigos citadosCitado por SciELO

Links relacionados

  • Não possue artigos similaresSimilares em SciELO

Compartilhar


Medicina (Buenos Aires)

versão impressa ISSN 0025-7680versão On-line ISSN 1669-9106

Resumo

FAINGOLD, María C. et al. Pharmacological and clinical characteristics of Insulin Faster Aspart (Fiasp®). Medicina (B. Aires) [online]. 2022, vol.82, n.5, pp.752-759. ISSN 0025-7680.

Fast acting aspart insulin is a faster-acting formulation of aspart insulin, having nicotinamide and L-arginine added to the molecule, in order to achieve a faster absorption through the subcutaneous cellular tissue. Pharmacokinetic and pharmacodynamic studies showed a left-shifted mean serum concentration-time profile compared to the conventional formulation. Its efficacy profile is highlighted in terms of early postprandial glycemic control. In addition, fast acting aspart insulin allows a more flexible treatment schedule, as it may be administrated at mealtime, immediately before or up to 20 minutes after; this schedule represents an advantage regarding quality of life in patients with diabetes treated with prandial insulin, especially in populations such as children, pregnant women or elderly subjects. The safety and tolerability profiles are comparable to conventional aspart insulin.

Palavras-chave : Aspart insulin; Pharmacokinetics; Pharmacodynamics; Posprandial glycemia.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )